PANCE Blueprint Pulmonary (9%)

Pulmonary Neoplasms (PEARLS)

The NCCPA™ PANCE Pulmonary System Content Blueprint (current edition) lists the following topics under neoplasms:

Pulmonary Neoplasms: Benign, Malignant, and Carcinoid (Neuroendocrine) Tumors

Condition Location & Features Treatment
Benign
Hamartoma Peripheral; benign with “popcorn” calcifications on imaging Observation; surgical removal if symptomatic
Pulmonary lipoma Peripheral; rare benign tumor of adipose tissue Observation or resection if symptomatic
Fibroma Variable; connective tissue origin, usually asymptomatic Observation
Papilloma Central (airways); squamous or glandular Surgical excision
Malignant
NSCLC - Adenocarcinoma Peripheral; most common subtype; common in nonsmokers Surgery ± chemo/immunotherapy
NSCLC - Squamous cell carcinoma Central; linked to smoking; may cavitate Surgery ± radiation/chemo
NSCLC - Large cell carcinoma Peripheral or central; aggressive, poor prognosis Surgery ± chemo/radiation
Small cell lung cancer (SCLC) Central; very aggressive, paraneoplastic syndromes common Chemoradiation; often unresectable
Mesothelioma Pleura; associated with asbestos exposure Systemic therapy (immunotherapy or chemotherapy); surgery in selected cases; palliative care
Pulmonary metastases Secondary tumors; Variable locations; multiple nodules, from breast, colon, kidney, melanoma, etc. Treat primary malignancy; palliative options
Carcinoid Tumors
Typical carcinoid tumor (low-grade neuroendocrine tumor; older texts call it a "bronchial adenoma") Central; slow-growing; may cause obstruction/hemoptysis Surgical resection
Atypical carcinoid tumor Central or peripheral; more aggressive Surgery ± adjuvant therapy
Carcinoid syndrome (rare) Systemic symptoms (flushing, diarrhea, wheezing) from serotonin secretion Octreotide; surgery if resectable
Pulmonary nodules
Patient will present as → a 35-year-old female who was found to have a small (2.5 cm) pulmonary lesion on chest radiograph found incidentally after a screening exam for a positive PPD at work. The patient has no significant past medical history, and the patient is asymptomatic.

≤ 3 cm is a nodule (coin lesion), and > 3 cm, the lesion is considered a "mass"

  • Smooth, well-defined edges are more likely to be benign
  • Ill-defined, lobular, or spiculated suggests cancer
  • Pulmonary nodules are also known as coin lesions

When managing pulmonary nodules, we follow the Fleischner Society's pulmonary nodule recommendations

Steps to dealing with a pulmonary nodule:

  • Incidental finding on CXR → compare to older films if available →
  • Send for CT →
  • If suspicious (depending on radiographic findings below), will need a biopsy
    • Ill-defined lobular or spiculated suggests cancer
  • If not suspicious, follow the Fleischner schedule: solid nodule under 6 mm in a low-risk patient → no routine follow-up; 6–8 mm → CT at 6–12 months; over 8 mm → CT at 3 months, PET-CT, or tissue sampling. A solid nodule stable for 2 years is benign
    • Calcification, smooth, well-defined edges, suggests benign disease

Thorax pa peripheres Bronchialcarcinom li OF markiert

Chest X-ray showing a solitary pulmonary nodule (indicated by a black box) in the left upper lobe. Image: Lange123 at German Wikipedia, CC BY-SA 3.0, via Wikimedia Commons.

Lung cancer (ReelDx)
Patient will present as → a 65-year-old woman with a 40-pack-year history of smoking presents with a 7 kg weight loss over the last 3 months and recent onset of streaks of blood in the sputum. PE reveals a thin, afebrile woman with clubbing of the fingers, an increased anteroposterior diameter, scattered and coarse rhonchi and wheezes over both lung fields, and distant heart sounds.

ReelDx Virtual Rounds (lung cancer)
Lung cancer is classified into 2 major categories

  1. Non–small cell lung cancer (NSCLC)—about 85% of cases
  2. Small cell lung cancer (SCLC)—about 15% of cases (BAD)

1. Non–Small Cell Lung Cancer (NSCLC) - About 85% of cases

Subtypes include: adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and carcinoid tumors (rare low-grade neuroendocrine tumors, classified separately from NSCLC).

  1. Adenocarcinoma
    • Most common subtype of NSCLC (35-40% of cases)
    • Common in non-smokers but also associated with smoking and asbestos exposure
    • Paraneoplastic syndrome: thrombophlebitis
    • Presentation → non-smoker, with an incidental finding of a small peripheral lesion
  2. Squamous Cell Carcinoma
    • 25-35% of cases
    • Typically central, arising from bronchial tissue, associated with smoking
    • Often causes hemoptysis due to tumor invading the central bronchus
    • Paraneoplastic syndrome: hypercalcemia (via PTHrP production)
    • Presentation → smoker with hemoptysis and a large central mass on imaging
  3. Large Cell Carcinoma
    • Rare (5% of cases)
    • Poorly differentiated, high-grade tumors
    • Typically peripheral (60%)
    • Paraneoplastic syndrome: gynecomastia
    • Presentation → smoker with a large peripheral mass, often asymptomatic until late-stage
  4. Carcinoid Tumors (Rare, 1-2% of all lung cancers)
    • Derived from neuroendocrine cells and can secrete serotonin, histamine, and bradykinin
    • Lung carcinoids are rare and usually primary bronchial tumors; GI carcinoids (most often small intestine) can also spread to the liver and lung
    • Presentation → hemoptysis, cough, focal wheezing, recurrent pneumonia; may cause carcinoid syndrome (flushing, diarrhea, wheezing, hypotension)
    • Note: Most carcinoid tumors are slow-growing and less aggressive compared to other lung cancers

2. Small Cell Lung Cancer (SCLC) - About 15% of cases

  • Extremely aggressive, almost exclusively seen in smokers
  • Rapid progression, with about two-thirds of cases extensive-stage (metastatic) at diagnosis
  • Poor prognosis, rarely surgical; treated with platinum-etoposide chemotherapy plus radiation (limited stage) or plus immunotherapy (extensive stage)
  • Paraneoplastic syndromes:
    • ACTH secretion → Cushing syndrome
    • ADH secretion → hyponatremia (SIADH)
    • Lambert-Eaton Myasthenic Syndrome: Autoantibodies affecting calcium channels → proximal muscle weakness

Lung Cancer Screening Guidelines

DX: Chest X-ray followed by CT scan, confirmed with biopsy (bronchoscopy, CT-guided needle biopsy, or thoracoscopy); stage with PET-CT and brain MRI; advanced non-small cell tumors need molecular testing (EGFR, ALK, ROS1 and others) and PD-L1

  • Staging: TNM system (Tumor, Node, Metastasis)

TX:

Non-small cell cancer can be treated with surgery

  • Treatment depends on staging:
    • Stage I-II: surgical resection (lobectomy); stereotactic radiation if not a surgical candidate
    • Stage III: usually concurrent chemoradiation followed by immunotherapy (durvalumab); selected resectable tumors get chemo-immunotherapy, then surgery
    • Stage IV: systemic therapy guided by molecular testing (targeted therapy for EGFR/ALK and other drivers, or immunotherapy ± chemotherapy)
    • Carcinoid tumors are treated with surgery

Small cell cancer is rarely treated with surgery (only very early, node-negative disease) and will need platinum-etoposide chemotherapy plus thoracic radiation (limited stage) or plus immunotherapy (extensive stage)

Associated manifestations:

  • Superior vena cava syndrome (facial/arm edema and swollen chest wall veins)
  • Pancoast tumor (shoulder pain, Horner’s syndrome, brachial plexus compression)
  • Horner’s syndrome (unilateral miosis, ptosis, and anhidrosis)
  • Carcinoid syndrome (flushing, diarrhea, and telangiectasia)

Small cell cancer of the lung with a typical centrally located mediastinal mass (seen here on the left)

Small cell cancer of the lung with a typical centrally located mediastinal mass (seen here on the left) Image: Yale Rosen from USA, CC BY-SA 2.0, via Wikimedia Commons.

Carcinoid tumors
Patient will present with → a 38-year-old nonsmoking woman who comes to the clinic with a persistent cough and recurrent pneumonia in the same lobe (the right middle lobe, three times in the past year), along with several episodes of blood-streaked sputum. She was told she has asthma, but inhalers have not helped. She denies flushing or diarrhea. On physical examination, there is a localized, fixed wheeze over the right mid-lung field. Chest CT reveals a well-circumscribed central endobronchial mass in the right middle lobe bronchus with post-obstructive atelectasis. Bronchoscopy shows a smooth, pink-purple, highly vascular lesion, and biopsy confirms a typical carcinoid tumor (chromogranin A positive).

A tumor arising from neuroendocrine cells → leading to excess secretion of serotonin, histamine, and bradykinin

  • Common primary sites include GI (small and large intestines, stomach, pancreas, liver), lungs, ovaries, and thymus
    • The most common site of a neuroendocrine (carcinoid) tumor to metastasize to is the liver
    • The small intestine (ileum) is the most common source of carcinoid syndrome, which appears once the tumor has spread to the liver; lung carcinoids are usually primary bronchial tumors, not metastases from the gut
  • Usually asymptomatic until liver metastasis; symptoms develop occasionally
    • GI tract tumor→ hormone secretion → enter the portal circulation → liver inactivates hormones → no symptoms
    • Liver tumor → hormone secretion → released into circulation + liver dysfunction → symptoms
  • Carcinoid syndrome (the hallmark sign) = Cutaneous flushing, diarrhea, wheezing and low blood pressure is actually quite rare and occurs in ~ 5% of carcinoid tumors and becomes manifest when vasoactive substances from the tumors enter the systemic circulation escaping hepatic degradation.
  • The syndrome includes flushing, ↑ intestinal motility (diarrhea), itching and less frequently, heart failure, vomiting, bronchoconstriction, asthma, and wheezing
    • ↑ Serotonin leads to collagen fiber thickening, fibrosis = heart valve dysfunction → tricuspid regurgitation, pulmonary stenosis/bronchoconstriction, and wheezing
    • ↑ Histamine and bradykinin = vasodilation and flushing
    • ↑ serotonin synthesis → ↓ tryptophan → ↓ niacin/B3 synthesis = pellagra

DX:

CT-Scan to locate the tumors

    • Somatostatin receptor imaging (Ga-68 DOTATATE PET, which has replaced the older Octreoscan) → a radiolabeled somatostatin analog binds to somatostatin receptors on tumor cells
    • 24-hour urine 5-hydroxyindoleacetic acid (5-HIAA) → the main metabolite of serotonin; best initial test when carcinoid syndrome is suspected (it can be normal with bronchial carcinoids)
    • Pellagra (niacin/B3 deficiency) - ↑ serotonin synthesis → ↓ tryptophan → ↓ niacin/B3 synthesis
    • CT of the chest shows a well-circumscribed central endobronchial mass, often with post-obstructive atelectasis or pneumonia
    • Bronchoscopy with biopsy confirms the diagnosis: a pink/purple, well-vascularized central lesion

Treatment is by surgical excision and carries a good prognosis

  • The lesions are relatively resistant to radiation therapy and chemotherapy
  • Octreotide or lanreotide - somatostatin analogs that bind somatostatin receptors and decrease the secretion of serotonin by the tumor, controlling carcinoid syndrome symptoms
  • Niacin supplementation

Carcinoid tumors are usually centrally located, arising in large airways

Carcinoid tumors are usually centrally located, arising in large airways. The arrow points to the tumor in the right hilar region. Image: Yale Rosen from USA, CC BY-SA 2.0, via Wikimedia Commons.

Tuberculosis (ReelDx + Lecture) (Prev Lesson)
(Next Lesson) Brian Wallace PA-C Podcast: Pulmonary Neoplastic Disease
Back to PANCE Blueprint Pulmonary (9%)

NCCPA™ CONTENT BLUEPRINT

🤖 NEW: Smarty PANCE now connects directly to your favorite AI tool. It builds custom exams from your weak areas, and it's included with your membership!

X